Michael Witcher

2.9k total citations · 1 hit paper
37 papers, 1.6k citations indexed

About

Michael Witcher is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Witcher has authored 37 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Witcher's work include Epigenetics and DNA Methylation (8 papers), Protein Degradation and Inhibitors (8 papers) and Genomics and Chromatin Dynamics (8 papers). Michael Witcher is often cited by papers focused on Epigenetics and DNA Methylation (8 papers), Protein Degradation and Inhibitors (8 papers) and Genomics and Chromatin Dynamics (8 papers). Michael Witcher collaborates with scholars based in Canada, United States and France. Michael Witcher's co-authors include Tatiana Shorstova, Beverly M. Emerson, William D. Foulkes, Maud Marques, Khalid Hilmi, Tiejun Zhao, Maïka Jangal, Satchidananda Panda, Luciano DiTacchio and Megumi Hatori and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Michael Witcher

37 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Achieving clinical success with BET inhibitors as anti-cancer agents

2021 224 citations Tatiana Shorstova, William D. Foulkes et al. British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Witcher Canada	21	1.3k	267	165	130	128	37	1.6k
Vishva M. Sharma United States	17	843 0.7×	236 0.9×	233 1.4×	160 1.2×	77 0.6×	26	1.4k
Thomas Åskov Pedersen Denmark	17	1.1k 0.9×	140 0.5×	165 1.0×	172 1.3×	21 0.2×	28	1.7k
Margaret A. Lawlor United Kingdom	8	1.3k 1.0×	204 0.8×	156 0.9×	83 0.6×	36 0.3×	10	1.6k
Anutosh Chakraborty United States	23	1.3k 1.0×	619 2.3×	187 1.1×	94 0.7×	184 1.4×	36	2.2k
Susumu Tanimura Japan	25	1.2k 1.0×	283 1.1×	210 1.3×	194 1.5×	37 0.3×	46	1.8k
Sonja Wolff Germany	11	1.4k 1.1×	603 2.3×	451 2.7×	110 0.8×	98 0.8×	13	1.8k
Roland Greimers Belgium	18	597 0.5×	227 0.9×	168 1.0×	95 0.7×	113 0.9×	67	1.4k
Susan K. Gilmour United States	26	1.5k 1.2×	191 0.7×	152 0.9×	82 0.6×	52 0.4×	58	1.9k
Laura Braccini Italy	8	880 0.7×	239 0.9×	273 1.7×	56 0.4×	39 0.3×	12	1.3k
Sen Zhang China	11	795 0.6×	161 0.6×	83 0.5×	70 0.5×	93 0.7×	24	1.0k

Countries citing papers authored by Michael Witcher

Since Specialization

Citations

This map shows the geographic impact of Michael Witcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Witcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Witcher more than expected).

Fields of papers citing papers by Michael Witcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Witcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Witcher. The network helps show where Michael Witcher may publish in the future.

Co-authorship network of co-authors of Michael Witcher

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Witcher. A scholar is included among the top collaborators of Michael Witcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Witcher. Michael Witcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Annis, Matthew G., Steven Hébert, Michael Witcher, et al.. (2024). The Neurodevelopmental Protein POGZ Suppresses Metastasis in Triple-Negative Breast Cancer by Attenuating TGFβ Signaling. Cancer Research. 84(22). 3743–3760. 3 indexed citations

Moussa, Omar, Christophe Gonçalves, Vincent R. Richard, et al.. (2024). Combined Inhibition of MNK Signaling and BET Proteins Reveals TGM2 as a Novel Vulnerability in Melanoma. Journal of Investigative Dermatology. 145(4). 979–984.e5. 1 indexed citations

Jangal, Maïka, Tiejun Zhao, Cheng Kit Wong, et al.. (2022). 3D chromatin remodeling potentiates transcriptional programs driving cell invasion. Proceedings of the National Academy of Sciences. 119(36). e2203452119–e2203452119. 10 indexed citations

Heath, John A., Vincent Luo, Xiaoru Chen, et al.. (2021). POGZ promotes homology‐directed DNA repair in an HP1‐dependent manner. EMBO Reports. 23(1). e51041–e51041. 13 indexed citations

Shorstova, Tatiana, William D. Foulkes, & Michael Witcher. (2021). Achieving clinical success with BET inhibitors as anti-cancer agents. British Journal of Cancer. 124(9). 1478–1490. 224 indexed citations breakdown →

Totten, Stephanie, Ryuhjin Ahn, Paul Savage, et al.. (2021). p66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors. JCI Insight. 6(4). 4 indexed citations

Shorstova, Tatiana, Jie Su, Tiejun Zhao, et al.. (2020). Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. Molecular Cancer Therapeutics. 20(1). 64–75. 9 indexed citations

Tischkowitz, Marc, Sidong Huang, Susana Banerjee, et al.. (2020). Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines. Clinical Cancer Research. 26(15). 3908–3917. 84 indexed citations

Spriano, Filippo, Eugenio Gaudio, Luciano Cascione, et al.. (2020). Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Advances. 4(17). 4124–4135. 53 indexed citations

10.

Shorstova, Tatiana, Maud Marques, Jie Su, et al.. (2019). SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors. Cancer Research. 79(10). 2761–2774. 52 indexed citations

11.

Jangal, Maïka, et al.. (2019). Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?. Expert Opinion on Therapeutic Targets. 23(7). 565–578. 27 indexed citations

12.

Marques, Maud, Maïka Jangal, Lichun Wang, et al.. (2018). Oncogenic activity of poly (ADP-ribose) glycohydrolase. Oncogene. 38(12). 2177–2191. 25 indexed citations

13.

Wan, Ji, Yoshihiko Fujita, Jagpreet S. Nanda, et al.. (2017). Competition between translation initiation factor eIF5 and its mimic protein 5MP determines non-AUG initiation rate genome-wide. Nucleic Acids Research. 45(20). 11941–11953. 59 indexed citations

14.

Saad, Amine, Krikor Bijian, Sabrina Daniela da Silva, et al.. (2016). Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2. Scientific Reports. 6(1). 36699–36699. 24 indexed citations

15.

Shorstova, Tatiana, et al.. (2016). Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1865(2). 275–288. 149 indexed citations

16.

Zhao, Tiejun, Qiang Sun, Maud Marques, & Michael Witcher. (2015). Anticancer Properties ofPhyllanthus emblica(Indian Gooseberry). Oxidative Medicine and Cellular Longevity. 2015. 1–7. 75 indexed citations

17.

Marques, Maud, et al.. (2014). Analysis of changes to mRNA levels and CTCF occupancy upon TFII-I knockdown. Genomics Data. 4. 17–21. 3 indexed citations

18.

Zhao, Tiejun, et al.. (2014). Gallotannin Imposes S Phase Arrest in Breast Cancer Cells and Suppresses the Growth of Triple-Negative Tumors In Vivo. PLoS ONE. 9(3). e92853–e92853. 25 indexed citations

19.

Panasci, Lawrence, et al.. (2012). Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?. Frontiers in Pharmacology. 3. 202–202. 4 indexed citations

20.

Witcher, Michael & Beverly M. Emerson. (2009). Epigenetic Silencing of the p16 Tumor Suppressor Is Associated with Loss of CTCF Binding and a Chromatin Boundary. Molecular Cell. 34(3). 271–284. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact